



Tanvex BioPharma USA, Inc. signed agreement in Japan

July 26, 2018

Tanvex BioPharma USA, Inc., a wholly-owned subsidiary of Tanvex BioPharma, Inc. ("Tanvex") (TWSE: 6541), has entered into an agreement with Linical Co. Ltd. ("Linical"), a global CRO headquartered in Japan.

Linical will provide partnering services to assist Tanvex in identifying and evaluating commercial partners for their trastuzumab and bevacizumab biosimilar candidates in Japan. In addition, Linical will provide regulatory services to support the registration of Tanvex's trastuzumab and bevacizumab biosimilar candidates in Japan.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.

About Linical

Linical Co., Ltd. is a Contract Research Organization (CRO) headquartered in Japan dedicated to providing a full range of professional services across the drug development process, with global operations in more than 20 countries. In accordance with the philosophy of contributing to new drug development and

promoting the happiness of patients, Linical has supported the clinical development efforts of clients, focusing mainly on oncology, CNS (central nervous system), and immunology. Linical is capable of delivering a one-stop set of comprehensive services for large-scale, global projects and offering a streamlined service, ranging from innovative drug development, clinical development, clinical research, and surveys after manufacturing and sale, to support the drug life cycle management.